Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Autor: Munir, T., Brown, J.R., O'Brien, Susan, Barrientos, J.C., Barr, P.M., Reddy, N.M., Coutre, S., Tam, C.S., Mulligan, S.P., Jaeger, U., Kipps, T.J., Moreno, Carol, Montillo, M., Burger, J.A., Byrd, J.C., Hillmen, Peter, Dai, S., Szoke, A., Dean, J.P., Woyach, J.A., Universitat Autònoma de Barcelona

Publikováno v: American journal of hematology, vol 94, iss 12
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
AMERICAN JOURNAL OF HEMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Recercat. Dipósit de la Recerca de Catalunya
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
American Journal of Hematology

Altres ajuts: The authors thank the patients who participated in this study and their supportive families, as well as the investigators, subinvestigators, and coordinators at each of the study sites. The authors thank Jerry Ping of Pharmacyclics LLC,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::683d9a60258a660edd146fe27a5e3bef
https://escholarship.org/uc/item/3vj2b32m

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

Autor: Young, E. Noerenberg, D. Mansouri, L. Ljungström, V. Frick, M. Sutton, L.-A. Blakemore, S.J. Galan-Sousa, J. Plevova, K. Baliakas, P. Rossi, D. Clifford, R. Roos-Weil, D. Navrkalova, V. Dörken, B. Schmitt, C.A. Smedby, K.E. Juliusson, G. Giacopelli, B. Blachly, J.S. Belessi, C. Panagiotidis, P. Chiorazzi, N. Davi, F. Langerak, A.W. Oscier, D. Schuh, A. Gaidano, G. Ghia, P. Xu, W. Fan, L. Bernard, O.A. Nguyen-Khac, F. Rassenti, L. Li, J. Kipps, T.J. Stamatopoulos, K. Pospisilova, S. Zenz, T. Oakes, C.C. Strefford, J.C. Rosenquist, R. Damm, F.

Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hots

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::8a1f09dcc6f090a2d6237af030848cb8
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3085766